Page last updated: 2024-08-16

suramin and o-(chloroacetylcarbamoyl)fumagillol

suramin has been researched along with o-(chloroacetylcarbamoyl)fumagillol in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Bruce, JN; Johnson, JP1
Kakeji, Y; Teicher, BA1
Kim, J; Logothetis, CJ1
Bu, W; Li, XM; Qin, LX; Tang, ZY; Xia, JL1
Libutti, SK; Zogakis, TG1

Reviews

3 review(s) available for suramin and o-(chloroacetylcarbamoyl)fumagillol

ArticleYear
Angiogenesis in human gliomas: prognostic and therapeutic implications.
    EXS, 1997, Volume: 79

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cyclohexanes; Endothelial Growth Factors; Epidermal Growth Factor; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Glioma; Humans; Lymphokines; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Prognosis; Sesquiterpenes; Suramin; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

1997
Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma.
    The Urologic clinics of North America, 1999, Volume: 26, Issue:2

    Topics: Androgen Antagonists; Antineoplastic Agents; Cyclohexanes; Humans; Male; O-(Chloroacetylcarbamoyl)fumagillol; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Suramin

1999
General aspects of anti-angiogenesis and cancer therapy.
    Expert opinion on biological therapy, 2001, Volume: 1, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antibodies; Clinical Trials as Topic; Collagen; Cyclohexanes; Endostatins; Endothelial Growth Factors; Fatty Acids, Unsaturated; Humans; Interleukin-12; Lymphokines; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Peptide Fragments; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Receptors, Vitronectin; RNA, Catalytic; Sesquiterpenes; Suramin; Thalidomide; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2001

Other Studies

3 other study(ies) available for suramin and o-(chloroacetylcarbamoyl)fumagillol

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
    Investigational new drugs, 1997, Volume: 15, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carmustine; Cell Division; Cisplatin; Cyclohexanes; Cyclophosphamide; Doxorubicin; Drug Synergism; Genistein; Isoflavones; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Minocycline; Neoplasm Invasiveness; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Random Allocation; Sesquiterpenes; Suramin

1997
Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma.
    Annals of the Academy of Medicine, Singapore, 1999, Volume: 28, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Division; Cyclohexanes; Liver Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Sesquiterpenes; Suramin; Thiophenes; Triazoles

1999